Drug intelligence / Profile preview

AVETT

Development stage: Preclinical
Lead developer: Avesthagen
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AVETT is a biosimilar candidate of abciximab (ReoPro), a chimeric monoclonal antibody fragment (Fab) developed by Avestha Gengraine Technologies (Avesthagen). It is designed to target and inhibit the glycoprotein IIb/IIIa (integrin alpha-IIb/beta-3) receptor on the surface of human platelets. By binding to this receptor, AVETT prevents the binding of fibrinogen, von Willebrand factor, and other adhesive molecules, thereby inhibiting the final common pathway of platelet aggregation. The drug is intended for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI) and is being explored for indications related to coronary artery disease and heart surgery. AVETT is currently in the preclinical development stage.

Other names: abciximab biosimilar

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on AVETT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVETT.

Explore the full profile